(VIANEWS) – BanColombia S.A. (CIB), ANI Pharmaceuticals (ANIP), Neurocrine Biosciences (NBIX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BanColombia S.A. (CIB)
52.9% sales growth and 16.94% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.55.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 4.43. Meaning, the purchaser of the share is investing $4.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.94%.
2. ANI Pharmaceuticals (ANIP)
39.5% sales growth and 3.38% return on equity
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings Per Share
As for profitability, ANI Pharmaceuticals has a trailing twelve months EPS of $0.54.
PE Ratio
ANI Pharmaceuticals has a trailing twelve months price to earnings ratio of 98.94. Meaning, the purchaser of the share is investing $98.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.38%.
3. Neurocrine Biosciences (NBIX)
25% sales growth and 10.77% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $1.9.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 69.87. Meaning, the purchaser of the share is investing $69.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.6%, now sitting on 1.78B for the twelve trailing months.
4. Merchants Bancorp (MBIN)
16.4% sales growth and 17% return on equity
Merchants Bancorp operates as the diversified bank holding company in the United States. It operates through Multi-family Mortgage Banking, Mortgage Warehousing, and Banking segments. The Multi-family Mortgage Banking segment engages in the mortgage banking, which originates and services government sponsored mortgages including bridge financing products to refinance, acquire, or reposition multi-family housing projects, and construction lending for multi-family and healthcare facilities; offers customized loan products for need-based skilled nursing facilities, independent living, assisted living, and memory care; and tax credit equity syndicator. Its Mortgage Warehousing segment funds agency eligible residential loans including origination, purchase, and sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment offers a range of financial products and services to consumers and businesses, which includes retail banking, commercial lending, agricultural lending, retail and correspondent residential mortgage banking, and small business administration lending. Merchants Bancorp was founded in 1990 and is headquartered in Carmel, Indiana.
Earnings Per Share
As for profitability, Merchants Bancorp has a trailing twelve months EPS of $5.17.
PE Ratio
Merchants Bancorp has a trailing twelve months price to earnings ratio of 7.79. Meaning, the purchaser of the share is investing $7.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17%.
5. Evertec (EVTC)
15.7% sales growth and 19.52% return on equity
EVERTEC, Inc. engages in transaction processing business in Latin America and the Caribbean. The company operates through Payment Services – Puerto Rico & Caribbean; Payment Services – Latin America; Merchant Acquiring; Business Solutions, and Corporate and Other segments. It provides merchant acquiring services, which enable point of sales and e-commerce merchants to accept and process electronic methods of payment, such as debit, credit, prepaid, and electronic benefit transfer (EBT) cards. The company also offers payment processing services that enable financial institutions and other issuers to manage, support, and facilitate the processing for credit, debit, prepaid, automated teller machines, and EBT card programs; credit and debit card processing, authorization and settlement, and fraud monitoring and control services to debit or credit issuers; and EBT services. In addition, it provides business process management solutions comprising core bank processing, network hosting and management, IT consulting, business process outsourcing, item and cash processing, and fulfillment solutions to financial institutions, and corporate and government customers. Further, the company owns and operates the ATH network, an automated teller machine and personal identification number debit networks. It manages a system of electronic payment networks that process approximately three billion transactions. The company sells and distributes its services primarily through direct sales force. It serves financial institutions, merchants, corporations, and government agencies. EVERTEC, Inc. was founded in 1988 and is headquartered in San Juan, Puerto Rico.
Earnings Per Share
As for profitability, Evertec has a trailing twelve months EPS of $1.51.
PE Ratio
Evertec has a trailing twelve months price to earnings ratio of 27.32. Meaning, the purchaser of the share is investing $27.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.52%.
6. NICE Ltd (NICE)
10.5% sales growth and 10.65% return on equity
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for CX that discovers automation opportunities for self-service; digital-entry points solutions that enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing. The company also provides smart self service solutions that empower organizations to build intelligent automated conversations based on data; and prepared agent solutions and tools enable contact center agents to guide and alert them in real time; complete performance solutions that help organizations to record structured and unstructured customer interaction and transaction data; and NICE Evidencentral, an digital evidence management platform for public safety emergency communications, law enforcement, and criminal justice helps agencies. In addition, it offers X-Sight, is an open and flexible AI-cloud platform for financial crime and compliance; Xceed, a cloud platform for comprehensive AML and fraud prevention for small and mid-sized organizations; data intelligence solutions that enable organizations to turn raw data into comprehensive actionable intelligence to prevent and detect financial crimes; AI and analytics technologies to detect and prevent financial crimes in real-time; money laundering and fraud prevention solutions that help organizations adhere to capital markets compliance and anti-money laundering compliance regulations; intelligent investigations solutions; and self-service solutions that provide organizations with customization and self-development capabilities. The company was formerly known as NICE-Systems Ltd. and changed its name to NICE Ltd. in June 2016. NICE Ltd. was founded in 1986 and is based in Ra'anana, Israel.
Earnings Per Share
As for profitability, NICE Ltd has a trailing twelve months EPS of $4.92.
PE Ratio
NICE Ltd has a trailing twelve months price to earnings ratio of 41.1. Meaning, the purchaser of the share is investing $41.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.65%.
Sales Growth
NICE Ltd’s sales growth is 8.4% for the ongoing quarter and 10.5% for the next.
Yearly Top and Bottom Value
NICE Ltd’s stock is valued at $202.23 at 00:22 EST, way under its 52-week high of $231.54 and way above its 52-week low of $149.54.
7. Assurant (AIZ)
8% sales growth and 12.3% return on equity
Assurant, Inc., together with its subsidiaries, provides lifestyle and housing solutions that support, protect, and connect consumer purchases in North America, Latin America, Europe, and the Asia Pacific. The company operates through three segments: Global Lifestyle, Global Housing, and Global Preneed. The Global Lifestyle segment provides mobile device protection products and services, and extended service contracts for consumer electronics and appliances, as well as assistance services; vehicle protection and related services; and credit and other insurance services. The Global Housing segment offers lender-placed homeowners insurance, manufactured housing, and flood insurance; and renters insurance and related products, as well as voluntary manufactured housing insurance, homeowners insurance, and other specialty products. The Global Preneed segment provides pre-funded funeral insurance, final need insurance, and related services. The company was formerly known as Fortis, Inc. and changed its name to Assurant, Inc. in February 2004. Assurant, Inc. was founded in 1892 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Assurant has a trailing twelve months EPS of $9.81.
PE Ratio
Assurant has a trailing twelve months price to earnings ratio of 16.82. Meaning, the purchaser of the share is investing $16.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.3%.
Previous days news about Assurant(AIZ)
- According to Zacks on Tuesday, 26 December, "While Assurant currently sports a Zacks Rank #1 (Strong Buy), Brown & Brown and Hartford Financial Services presently carry a Zacks Rank #2. "
- Here's why assurant (aiz) stock is investors' favorite now. According to Zacks on Tuesday, 26 December, "Shares of Assurant Inc. (AIZ Quick QuoteAIZ – Free Report) have rallied 32.6% year to date, outperforming 1.9%, 14.9% and 25% growth of the industry, the Finance sector and the Zacks S&P 500 composite, respectively, in the same time frame. "
- Zacks.com featured highlights include beacon roofing supply, deckers outdoor, a. o. smith assurant and tradeweb markets. According to Zacks on Tuesday, 26 December, "Chicago, IL - December 26, 2023 - Stocks in this week’s article are Beacon Roofing Supply (BECN Quick QuoteBECN – Free Report) , Deckers Outdoor (DECK Quick QuoteDECK – Free Report) , A. O. Smith (AOS Quick QuoteAOS – Free Report) , Assurant (AIZ Quick QuoteAIZ – Free Report) and Tradeweb Markets (TW Quick QuoteTW – Free Report) ."
- According to Zacks on Wednesday, 27 December, "Investors interested in Insurance – Multi line stocks are likely familiar with Assurant (AIZ Quick QuoteAIZ – Free Report) and Goosehead Insurance (GSHD Quick QuoteGSHD – Free Report) . "
